TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28754306

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 61
Study: 26138125

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Medically indicated GA
Number of subjects: 434

Group type: COMPARATOR
Intervention: Local Anesthesia
Number of subjects: 434
Study: 24712573

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU weekly for 8 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 22052304

Group type: COMPARATOR
Intervention: Alexandrite laser alone (four sessions, two months apart)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sequential treatment with diode laser for the first two sessions and alexandrite laser for the next two sessions
Number of subjects: 111

Group type: COMPARATOR
Intervention: Alexandrite laser alone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sequential treatment with diode and alexandrite lasers
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 111
Study: 19380259

Group type: EXPERIMENTAL
Intervention: Cupping therapy (wet cupping), single application
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (local application of heat over trapezius muscle), single application
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cupping therapy
Number of subjects: 52
Study: 17374834

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 579

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 579
Study: 15080781

Group type: EXPERIMENTAL
Intervention: Body mass reduction alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Body mass reduction plus rGH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Body mass reduction plus nandrolone undecanoate
Number of subjects: 20
Study: 11281433

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide/1% clindamycin
Number of subjects: 492

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide
Number of subjects: 492

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide/3% erythromycin
Number of subjects: 492
Study: 9277426

Group type: EXPERIMENTAL
Intervention: Liquid distension (100 ml)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Warm stimulation (47 +/- 1 degrees C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cold stimulation (18 +/- 2 degrees C)
Number of subjects: 9
Study: 7960314

Group type: EXPERIMENTAL
Intervention: Plain aspirin (1000mg of ASA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chewable buffered aspirin (1000mg of ASA and 600 mg of calcium carbonate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2955979

Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30409107

Group type: EXPERIMENTAL
Intervention: Levodopa 'on' (n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Levodopa 'off' (n = 13)
Number of subjects: 27
Study: 26981530

Group type: EXPERIMENTAL
Intervention: Cancer related fatigue (CRF)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Patients reporting CRF
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Qualitative themes from interviews
Number of subjects: 148
Study: 24091250

Group type: EXPERIMENTAL
Intervention: Treadmill training based real-world video recording (TRWVR) for 30 min per day, three times per week, for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treadmill walking training for 30 min per day, three times per week, for 6 weeks
Number of subjects: 30
Study: 22418044

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20869783

Group type: EXPERIMENTAL
Intervention: Physicians from the higher ranked institution
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Physicians from the lower ranked institution
Number of subjects: 30000
Study: 18418219

Group type: EXPERIMENTAL
Intervention: Interferon-alpha + gefitinib (500 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Interferon-alpha + imatinib (600 mg daily)
Number of subjects: 17
Study: 16185205

Group type: EXPERIMENTAL
Intervention: T‐ACASI
Number of subjects: 2287
Study: 12230146

Group type: EXPERIMENTAL
Intervention: Sequential presentation of symbols on video lottery terminals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous presentation of symbols on video lottery terminals
Number of subjects: 0
Study: 10220634

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol 10/100 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 397

Group type: COMPARATOR
Intervention: Metoprolol 100 mg
Number of subjects: 397
Study: 7783459

Group type: EXPERIMENTAL
Intervention: Composite acupuncture treatment (acupuncture, auriculo‐acupoint pellet pressure, herbal plasters)
Number of subjects: 128
Study: 2225438

Group type: EXPERIMENTAL
Intervention: Hancock bioprosthetic valves (n = 35)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Carpentier‐Edwards bioprosthetic valves (n = 40)
Number of subjects: 75
Study: 353087

Group type: EXPERIMENTAL
Intervention: Periodontal dressing 1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Periodontal dressing 2
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Periodontal dressing 3
Number of subjects: 41
Study: 31771639

Group type: EXPERIMENTAL
Intervention: New multi‐component service pathway (self‐management kit, customized GP checklist, educational topics)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: New multi‐component service pathway
Number of subjects: 110
Study: 28012773

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 557

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study: 25778333

Group type: COMPARATOR
Intervention: Combined general-epidural anesthesia (C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: General anesthesia (G)
Number of subjects: 40
Study: 23398140

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20697791

Group type: EXPERIMENTAL
Intervention: Reciprocal imitation training
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Video modeling
Number of subjects: 6
Study: 19244883

Group type: EXPERIMENTAL
Intervention: GTRF treatment (bioabsorbable membrane and demineralized xenograft)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CAF treatment (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatments (CAF and GTRF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GTRF treatment
Number of subjects: 16
Study: 16906456

Group type: EXPERIMENTAL
Intervention: Crossover design
Number of subjects: 200

Group type: COMPARATOR
Intervention: Parallel group design
Number of subjects: 200
Study: 14720302

Group type: EXPERIMENTAL
Intervention: Power Doppler (PD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional imaging (Duplex and Color Doppler)
Number of subjects: 18
Study: 11342889

Group type: EXPERIMENTAL
Intervention: Nonstented
Number of subjects: 58

Group type: COMPARATOR
Intervention: Stented
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 9331924

Group type: EXPERIMENTAL
Intervention: Subthreshold visual stimuli in the oddball-like paradigm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suprathreshold stimuli in the single-stimulus paradigm
Number of subjects: 0
Study: 8096228

Group type: EXPERIMENTAL
Intervention: Nebivolol (1 to 5 mg/day, n = 11)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 24
Study: 3959558

Group type: EXPERIMENTAL
Intervention: Alcohol (intoxicated condition)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sober condition (control)
Number of subjects: 40
Study: 30672976

Group type: EXPERIMENTAL
Intervention: Simulator model group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Animal model group
Number of subjects: 2
Study: 28334430

Group type: EXPERIMENTAL
Intervention: Wide margins (≥10 mm, WM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Narrow margins (≥5 mm but <10 mm, NM)
Number of subjects: 96
Study: 25810449

Group type: EXPERIMENTAL
Intervention: Electronic health record-based tools including reminders to measure height and weight, alerts for adding overweight or obesity to the problem list, tailored management recommendations, and a Weight Management screen
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Electronic health record-based tools
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no electronic health record-based tools)
Number of subjects: 23
Study: 23487178

Group type: EXPERIMENTAL
Intervention: Health warning by physicians that half of all smokers would be killed by smoking, advice to quit immediately and referral to a cessation clinic.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study: 21332712

Group type: EXPERIMENTAL
Intervention: GRASPA(®) 50 iu/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GRASPA(®) 100 iu/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GRASPA(®) 150 iu/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: E. colil‐ASNase (control)
Number of subjects: 24
Study: 19595257

Group type: EXPERIMENTAL
Intervention: Endosteal(TM) plus TP regimen
Number of subjects: 36

Group type: COMPARATOR
Intervention: TP regimen only
Number of subjects: 36
Study: 16652135

Group type: EXPERIMENTAL
Intervention: oral freeze-dried NT 6 gm/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: bed-dried NT 6 gm/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: freeze-dried NT 12 gm/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 15322434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Opioid blockade with naloxone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Negative Blockade Effects (ie, absence of endogenous opioid analgesia to acute pain) in the High Disability group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Positive Blockade Effects (ie, effective opioid analgesia to acute pain) in the Low Disability group
Number of subjects: 28
Study: 11094665

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine skin infiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study: 8925352

Group type: EXPERIMENTAL
Intervention: Low-dose depot haloperidol (25 mg) combined with targeted oral neuroleptics
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard-dose depot haloperidol (150 mg) combined with targeted oral neuroleptics
Number of subjects: 19
Study: 1562782

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus nutritional oral supplementation (Ensure)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 23
Study: 4060730

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tolazoline (Control)
Number of subjects: 36
Study: 3579004

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (enteral formula) in addition to usual diet for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (usual diet without enteral formula)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Comparison of RMF between poorly nourished and well-nourished male patients
Number of subjects: 21
Study: 31757519

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine lozenge used 15 minutes before cue exposure
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo lozenge used 15 minutes before cue exposure
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment until after cue presentation
Number of subjects: 58
Study: 29223019

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 221

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Presence of PNI
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Extramural vascular invasion
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Tumour budding
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: ≥2 adverse biomarkers
Number of subjects: 221
Study: 29145890

Group type: EXPERIMENTAL
Intervention: 0.5 mg metolazone single dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg metolazone single dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg metolazone single dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5 mg metolazone multiple doses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg metolazone with food effect
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metolazone (all doses)
Number of subjects: 30
Study: 26717214

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait therapy with the Lokomat® system
Number of subjects: 5
Study: 24370208

Group type: EXPERIMENTAL
Intervention: Specialist medical care plus the Lightning Process (LP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Specialist medical care (SMC)
Number of subjects: 80
Study: 22333097

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS) inserted immediately after artificial abortion
Number of subjects: 166

Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS) inserted during the period of regular menstruation
Number of subjects: 166
Study: 18451188

Group type: EXPERIMENTAL
Intervention: Nefiracetam 900 mg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: COMPARATOR
Intervention: Nefiracetam 600 mg
Number of subjects: 159
Study: 16544963

Group type: EXPERIMENTAL
Intervention: 375 mg bd acetazolamide
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 125 mg bd acetazolamide
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 12816549

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg/day) + lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo + lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Number of subjects: 45
Study: 10750574

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9185746

Group type: EXPERIMENTAL
Intervention: Low-dose MEG-X test (50 mg lidocaine intravenously)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard MEG-X test
Number of subjects: 70
Study: 1524688

Group type: EXPERIMENTAL
Intervention: Rembrandt with placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: Crest with Peridex
Number of subjects: 65

Group type: COMPARATOR
Intervention: Crest with placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: Peridex groups
Number of subjects: 65
Study: 2866788

Group type: EXPERIMENTAL
Intervention: Azepexole 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine 300 micrograms
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31119206

Group type: EXPERIMENTAL
Intervention: O6-PUFA (soybean oil, 6 g/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: O3-PUFA (fish oil, 6 g/d)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: O6-PUFA
Number of subjects: 81
Study: 27738125

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including transplant education and engagement activities targeting dialysis facility leadership, staff, and patients conducted from January to December of 2014.
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Control facilities (no specific intervention mentioned).
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (specifically for black patients).
Number of subjects: 9000
Study: 26001894

Group type: EXPERIMENTAL
Intervention: Continuous contact lens wear for 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-hour contact lens wear stages (C, D, E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No contact lenses worn (Stage A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of each 4-hour stage with no-lens response
Number of subjects: 0
Study: 24229013

Group type: EXPERIMENTAL
Intervention: Excision after injection of H202 without closure
Number of subjects: 142

Group type: COMPARATOR
Intervention: Excision and primary closure
Number of subjects: 142

Group type: COMPARATOR
Intervention: Excision after using hydrogen peroxide (H202) and primary closure
Number of subjects: 142

Group type: COMPARATOR
Intervention: Excision without closure
Number of subjects: 142
Study: 21328327

Group type: EXPERIMENTAL
Intervention: Bortezomib + Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 0
Study: 19150968

Group type: EXPERIMENTAL
Intervention: Computerized test battery for Alzheimer's disease screening
Number of subjects: 174
Study: 17225706

Group type: EXPERIMENTAL
Intervention: Leukotriene inhibitors
Number of subjects: 0
Study: 15277423

Group type: EXPERIMENTAL
Intervention: Stress testing and 5-year clinical follow-up
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Follow-up only (Control)
Number of subjects: 1123
Study: 11603537

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coated femoral stems
Number of subjects: 50

Group type: COMPARATOR
Intervention: Grit blasted (GB) femoral stems
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 9437311

Group type: EXPERIMENTAL
Intervention: Intracameral carbachol 0.01% (50:50 dilution)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 7666122

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg) administered as a single dose for three days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (amoxicillin 875 mg‐clavulanic acid 125 mg) given b.i.d. for 8 days
Number of subjects: 142
Study: 2757896

Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Angiotensin II with placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Angiotensin II with noradrenaline
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Noradrenaline and Angiotensin II combination
Number of subjects: 7
Study: 850321

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control (no diethylstilbestrol exposure)
Number of subjects: 320
Study: 30940090

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Simeprevir with ribavirin (n=63) for 12 or 24 weeks
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Simeprevir without ribavirin (n=536) for 12 or 24 weeks
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Severity of liver disease
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 599
Study: 28401844

Group type: EXPERIMENTAL
Intervention: High-quality foster care
Number of subjects: 111

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 111

Group type: COMPARATOR
Intervention: Comparison group (never institutionalized)
Number of subjects: 111
Study: 25595665

Group type: EXPERIMENTAL
Intervention: Strategy training (1 session per day, 5 days per week, in addition to usual inpatient rehabilitation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reflective listening (same dose as strategy training)
Number of subjects: 30
Study: 23973378

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hydromorphone (HM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both Methadone and Hydromorphone
Number of subjects: 14
Study: 21242545

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 131
Study: 19884223

Group type: EXPERIMENTAL
Intervention: Therapist-led group treatment
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Therapist-assisted group treatment
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Self-help group treatment
Number of subjects: 259

Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 259
Study: 17239492

Group type: EXPERIMENTAL
Intervention: 0,1,4 month vaccination schedule
Number of subjects: 615

Group type: COMPARATOR
Intervention: 0,1,6 month vaccination schedule
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Both vaccination schedules
Number of subjects: 615
Study: 14971964

Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate (CHO) supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate (CHO)
Number of subjects: 9
Study: 11346705

Group type: EXPERIMENTAL
Intervention: G‐CSF + EPO
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GM‐CSF + EPO
Number of subjects: 40
Study: 9040797

Group type: EXPERIMENTAL
Intervention: Bovine thrombin (20,000 units)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No thrombin (control)
Number of subjects: 101
Study: 7931444

Group type: EXPERIMENTAL
Intervention: Org 2766 (2 mg/day for 5 consecutive days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of Org 2766 vs Placebo
Number of subjects: 42
Study: 3060219

Group type: EXPERIMENTAL
Intervention: First screen mammography
Number of subjects: 44718
Study: 31954541

Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nurse-based intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 33
Study: 29973212

Group type: EXPERIMENTAL
Intervention: AS+SP (artesunate + sulfadoxine-pyrimethamine)
Number of subjects: 248

Group type: COMPARATOR
Intervention: AS+MQ (artesunate + mefloquine)
Number of subjects: 248
Study: 26236767

Group type: EXPERIMENTAL
Intervention: HOPE social media intervention (peer-mentored Facebook groups)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Enhanced standard of care (control group)
Number of subjects: 556